Clinuvel Pharmaceuticals (CUV) may not be as close to commercialising its technology compared with some of its peers, but all signs indicate that the photo-protective drug developer is on track to turn in a maiden profit in 2011-12.

Management reported positive phase II clinical trial results yesterday for its drug used to treat patients who are suffering from phototoxicity (ultraviolet light sensitivity that could result in second-degree burns when exposed to sunlight) as a side effect of certain cancer therapies.